Inspire Medical Systems, Inc. logo

Inspire Medical Systems, Inc. (INSP)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
40. 44
-0.14
-0.345%
$
1.17B Market Cap
- P/E Ratio
- Div Yield
1.14M Volume
-1.18 Eps
$ 40.58
Previous Close
Add Transaction
Day Range
38.91 40.6
Year Range
38.91 147.03
Want to track INSP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises

Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises

Inspire Medical (INSP) reports strong second-quarter results, reflecting a 30% revenue increase. Its new technology and expanded U.S. presence promise growth and enhanced patient care.

Zacks | 1 year ago
Inspire Medical Systems, Inc. (INSP) Q2 2024 Earnings Call Transcript

Inspire Medical Systems, Inc. (INSP) Q2 2024 Earnings Call Transcript

Inspire Medical Systems, Inc. (INSP) Q2 2024 Earnings Call Transcript

Seekingalpha | 1 year ago
Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics

Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 year ago
Inspire Medical Systems (INSP) Tops Q2 Earnings Estimates

Inspire Medical Systems (INSP) Tops Q2 Earnings Estimates

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.41 per share a year ago.

Zacks | 1 year ago
Inspire Medical (INSP) Gets FDA Nod for Inspire V System

Inspire Medical (INSP) Gets FDA Nod for Inspire V System

Inspire Medical (INSP) secures FDA approval for its advanced Inspire V therapy system, featuring an innovative neurostimulator and Bluetooth technology for enhanced patient and physician control.

Zacks | 1 year ago
Wall Street's Insights Into Key Metrics Ahead of Inspire (INSP) Q2 Earnings

Wall Street's Insights Into Key Metrics Ahead of Inspire (INSP) Q2 Earnings

Besides Wall Street's top -and-bottom-line estimates for Inspire (INSP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Zacks | 1 year ago
Sleep Apnea Device Marker Inspire's Stock Rises on Improved Outlook

Sleep Apnea Device Marker Inspire's Stock Rises on Improved Outlook

Inspire Medical Systems (INSP) shares rose Monday after the maker of an implanted device to treat sleep apnea released preliminary results and updated guidance that beat forecasts.

Investopedia | 1 year ago
Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval

Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval

Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.

Zacks | 1 year ago
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028

Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028

The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.

Zacks | 1 year ago
FDA Labels Inspire Medical's Sleep Apnea Nerve Stimulator Recall As Most Serious

FDA Labels Inspire Medical's Sleep Apnea Nerve Stimulator Recall As Most Serious

The FDA has labeled a recall of Inspire Medical Systems, Inc.'s INSP nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind.

Benzinga | 1 year ago
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?

Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?

Inspire (INSP) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Three Reasons to Retain Inspire Medical (INSP) Stock for Now

Three Reasons to Retain Inspire Medical (INSP) Stock for Now

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Zacks | 2 years ago